



**Section 4**  
**Health effects**

**Test Guideline No. 444A**  
*In vitro immunotoxicity*

*IL-2 Luc Assay*

4 July 2023

**OECD Guidelines for the  
Testing of Chemicals**



# OECD GUIDELINE FOR THE TESTING OF CHEMICALS

## In Vitro Immunotoxicity: Il-2 Luc Assay

### INITIAL CONSIDERATIONS AND LIMITATIONS

1. Immunotoxicology is defined as the study of adverse effects on any part of the immune system as the result of exposure to drugs or chemicals (1). Immunotoxicology can also include adverse effects on different organs and tissues mediated by cells and molecules of the immune system. The immune system is susceptible to toxic insults, in part because of: 1) the need to maintain the delicate balance between activation, regulation and silencing; 2) its dependence on regeneration of cells from hematopoietic stem cells in the bone marrow; 3) its requirement of clonal expansion of T cells and B cells by cellular proliferation during the adaptive response; and 4) the required maintenance of appropriate levels of lymphocytes, including effector, memory and naïve subsets.

2. Immunotoxicity by drugs or chemicals can be manifested in various ways, including dysregulation of the immune response, which could lead to immunosuppression or inappropriate immune stimulation. The latter can include exaggerated immune stimulation, sustained inflammation, hypersensitivity reactions and autoimmune diseases. With reference to chemical-induced immunotoxicity, the effect may not be exclusively in one direction and the same substance can produce immunosuppression or immune stimulation, depending on the dose and the cellular target. Thus, it may be more appropriate to define an immunotoxic substance as any agent that can alter one or more immune functions resulting in an adverse effect for the host. In this way, the focus is not on the direction of the effect, but on its consequence. For this reason, the term immunotoxicant/immunotoxicity is used in this TG, which is consistent with the Detailed Review Paper on immunosuppression that was developed by OECD (2).

3. From the OECD Adverse Outcome Pathway (AOP) development programme, AOP 154 “Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response” was approved in 2021 (3). This AOP describes calcineurin (CN) activity inhibition by binding of stressors, i.e., CN inhibitors (CNIs). CNIs bind to CN with their respective immunophilins, which interferes with the nuclear localization of nuclear factor of activated T cells (NFAT), a substrate of CN. As a result, the formation of functional NFAT complexes with activator protein-1 (AP-1) that bind at the site of IL-2, IL-4 and other T cell-derived cytokine promoters, is reduced, thereby suppressing production of these cytokines. Among the affected cytokines from each of the helper T cell subsets, reduced production of IL-2 and IL-4 negatively affects the proliferation and differentiation of B cells to suppress the T cell-dependent antibody response (TDAR).

4. IL-2 exerts pleiotropic actions on CD4+ T cell differentiation via its modulation of cytokine receptor expression. IL-2 promotes Th1 differentiation by inducing IL-12R $\beta$ 2 (and IL-12R $\beta$ 1), promotes Th2 differentiation by inducing IL-4R $\alpha$ , inhibits Th17 differentiation by inhibiting gp130 (and IL-6R $\alpha$ ), and drives Treg differentiation by inducing IL-2R $\alpha$ . IL-2 also potently represses IL-7R $\alpha$ , which decreases survival signals that normally promote cell survival and memory cell development (4) therefore conceivable that chemicals that affect IL-2 release by T cells can significantly impact immune function.

5. The IL-2 luciferase assay (IL-2 Luc assay) uses 2H4 cells to identify the effects of chemicals on the IL-2 and IFN- $\gamma$  promoters in the presence of the stimulants phorbol 12-myristate 13-acetate (PMA) and ionomycin (10) (5). 2H4, derived from Jurkat cells, contains stable luciferase green (SLG) regulated by the IL-2 promoter, stable luciferase orange (SLO) regulated by the interferon (IFN)- $\gamma$  promoter, and stable luciferase red (SLR) regulated by the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) promoter. Compared to methods that directly measure IL-2 and IFN produced by Jurkat cells, the IL-2 Luc assay significantly reduce both manual lab or and assay time. Specifically, the IL-2 Luc assay requires only the manual process of diluting chemicals and dispensing chemical solution and cells. In addition, IL-2 and IFN can be quantified by ELISA, but not the amount of GAPDH.

6. The validation study of the IL-2 Luc assay was conducted by a validation management team (VMT) composed of a lead laboratory, three independent laboratories, and four international expert members coordinated by the Japanese Center for the Validation of Alternative Methods (JaCVAM). This validation study met the acceptance criteria regarding within- (80.0%,4/5) and between-laboratory reproducibility (80.0%, 16/20) which could satisfy the acceptance criteria of 80% (6). To determine the predictivity, we collected immunotoxicological information and selected the reference data by classifying the chemical into immunotoxic compounds targeting T cells or others according to previously reported criteria. When compared with the reference data, the average sensitivity, specificity and predictivity in the validation study were 75.0% (36/48), 75.0% (18/24), and 75.0% (54/72), respectively (7), while the predictivity of an additional 60 chemicals was examined by the lead laboratory resulting in sensitivity, specificity and predictivity of 82.4% (28/34), 83.3% (5/6), and 82.5% (33/40), respectively. These results were reviewed by an international peer review panel. While the predictive capacity was not satisfactory for a stand-alone method, the IL-2 Luc assay is acceptable for use in an Integrated Approach to Testing and Assessment (IATA) (8). The IL-2 Luc assay provides a rapid screening tool that can be used as part of a systematic assessment of immunotoxicity when combined with other immunotoxicity tests.

7. Currently, the assessment of chemical immunotoxicity relies mainly on animal models and assays that characterise immunosuppression and sensitization. However, animal studies have many drawbacks, such as high cost, ethical concerns, and have varying ability to predict effects on human health (9). In addition, current *in vivo* models do not always provide a mechanistic understanding of the data. Overcoming these problems requires the development of *in vitro* methods to detect immunotoxicity. A workshop hosted by the European Centre for the Validation of Alternative Methods in 2003 focused on state-of-the-art *in vitro* systems for evaluating immunotoxicity (10)(11)(12) and a tiered approach was proposed. Within the tiered approach, the Multi-ImmunoTox assay (MITA) evaluates the effects of chemicals on the IL-2, IFN- $\gamma$ , IL-1 $\beta$ , and IL-8 promoters using three stable reporter cell lines (13)(14).

8. The purpose of this Test Guideline (TG) is to describe the procedure used to evaluate the potential immunotoxic effects of chemicals on T cells. The IL-2 Luc Assay is an important method for evaluating the immunotoxic potential of chemicals as a part of a battery (JaCVAM, 2020b), because of its technical simplicity, short test duration and accuracy of the test result, based on a known mechanism of immunotoxicity. The IL-2 Luc assay is applicable to soluble test chemicals or that test chemicals that form a stable dispersion and shares the same limitations that are common to many suspension cell-based assays when testing highly hydrophobic substances. Test chemicals that interfere with luciferase can confound its activity/measurement, causing apparent inhibition or increased luminescence (15). In addition, the following limitations should be noted: (1) the method cannot detect immunotoxicity associated with inhibition of DNA synthesis and cell division (7)(13); (2) the assay cannot detect test chemicals that require metabolic activation to form an immunotoxic metabolite (7)(13).

### **Specific limitations**

9. The following limitations should be noted: 1) the use of PMA/Io as a stimulant bypasses signalling through the T cell receptor and the subsequent intracellular signalling events that precede activation of phospholipase C, and therefore precludes detection of chemicals that act on those upstream signalling molecules (16); 2) the Jurkat T cell line (from which 2H4 cells are derived) are demonstrated to be suitable for examining the molecular mechanism underlying immunotoxicity (17), they may lack several key proteins involved in the activation of normal T cells in response to TCR stimulation, and therefore may not be able to detect effects of chemicals that act on those key proteins.

10. Definitions are provided in Appendix I.

### **PRINCIPLE OF THE TEST**

11. The IL-2 Luc assay makes use of a human acute T lymphoblastic cell line Jurkat that was obtained from Professor Kazuo Sugamura, Department of Microbiology, Tohoku University School of Medicine. Using this cell line, Tsuruga Institute of Biotechnology, TOYOBO Co., Ltd, established a Jurkat-derived IL-2 reporter cell line, 2H4, that harbors SLG, SLO and SLR luciferase genes under the control of the IL-2, IFN- $\gamma$ , and GAPDH promoters, respectively (5). Laboratories willing to perform the test can obtain the recombinant 2H4 cell line from Tottori Bioscience Promotion Organization, Tottori, Japan, upon signing a Material Transfer Agreement (MTA). This cell line allows quantitative measurement of luciferase gene induction by detecting luminescence from well-established light producing luciferase substrates as indicators of the activity of IL-2, IFN- $\gamma$  and GAPDH in cells following exposure to immunotoxic chemicals. To simplify the assay, only the IL-2 promoter driven luciferase activity (IL2LA) and GAPDH promoter driven luciferase activity have been used based on the following observations described in the literature (14). Most of chemicals examined by 2H4 cells showed similar suppressive effects on IL2LA and IFN promoter-driven luciferase activity (IFNLA). In addition, when the lowest observed effect level (LOELs) of these chemicals were plotted against their effects on IL-2LA and those on IFNLA, they showed a significant correlation between them. Therefore, a decision was made to only use IL2LA.

12. The multicolour assay system (18)(19) comprises a green-emitting luciferase (SLG;  $\lambda_{\max}$  = 550 nm) (20) for the gene expression of the IL-2 promoter, an orange-emitting luciferase (SLO;  $\lambda_{\max}$  = 580 nm) (21) for the gene expression of the IFN- $\gamma$ , promoter as well as a red-emitting luciferase (SLR;  $\lambda_{\max}$  = 630 nm) (22) for the gene expression of the internal control promoter, GAPDH. The three luciferases emit different colours upon reacting with firefly D-luciferin and their luminescence is measured simultaneously in a one-step reaction by dividing the emission from the assay mixture using two optical filters (18) (see Appendix II). For accurate luminescence measurements, a highly sensitive luminescence meter (e.g. a luminescence meter dedicated to luminescence measurements as described in Appendix II) should be used.

13. 2H4 cells are treated for 1 hour with the test chemical, and then treated for 6 hours with PMA and Io after which SLG luciferase activity (SLG-LA) reflecting IL-2 promoter activity, SLO luciferase activity (SLO-LA) reflecting IFN- $\gamma$  promoter activity and SLR luciferase activity (SLR-LA) reflecting GAPDH promoter activity are measured. To make the abbreviations easier to understand, SLG-LA, SLO-LA and SLR-LA are designated as IL2LA, IFNLA and GAPLA, respectively. Table 1 provides a description of the terms associated with luciferase activity in the IL-2 Luc assay. The measured values are used to calculate the normalised IL2LA (nIL2LA) and IFNLA (nIFNLA), which is the ratio of IL2LA and IFNLA to GAPLA, respectively, and the inhibition of GAPLA (Inh-GAPLA), which is the ratio of the arithmetic means of quadruple-measured values of the GAPLA of 2H4 cells treated with a test chemical and the values of the GAPLA of untreated 2H4 cells, and used as an indicator for cytotoxicity. The % suppression, calculated as shown in the table, indicates the effect of tested chemicals on IL-2 and IFN- $\gamma$  promoter.

Table 1. Description of terms associated with the luciferase activity in the IL-2 Luc assay

Abbreviations	Definition
IL2LA	SLG luciferase activity reflecting IL-2 promoter activity
IFNLA	SLO luciferase activity reflecting IFN- $\gamma$ promoter activity
GAPLA	SLR luciferase activity reflecting GAPDH promoter activity
nIL2LA	IL2LA / GAPLA
nIFNLA	IFNLA / GAPLA
Inh-GAPLA	GAPLA of 2H4 treated with chemicals / GAPLA of untreated cells
% suppression	$(1 - (\text{nIL2LA of 2H4 treated with chemicals}) / (\text{nIL2LA of non-treated 2H4})) \times 100$
CV05	The lowest concentration of the test chemical at which Inh-GAPLA becomes $<0.05$ .

14. The IL-2 Luc assay can simultaneously examine GAPLA and IL2LA. GAPDH mRNA is ubiquitously expressed at moderately abundant levels. It is frequently used as an endogenous control for quantitative real time polymerase chain reaction in several experimental systems because its expression is constant at different times and after experimental manipulation (23)(24)(25). In addition, the lead laboratory demonstrated that Inh-GAPLA is more sensitive in detecting dying cells than the percentage of propidium iodide (PI)-excluding cells and that cells showing Inh-GAPLA  $\geq 0.05$  maintain more than 75% of the PI-excluding cells. (26). Therefore, the results were evaluated using only data obtained in the concentration at which Inh-GAPLA is  $\geq 0.05$ .

## DEMONSTRATION OF PROFICIENCY

15. Prior to routine use of the test method described in Test Guideline, laboratories should demonstrate technical proficiency, using nine Proficiency Substances listed in Appendix III in compliance with the Good in vitro Method Practices (27). Moreover, test method users should maintain a historical database of data generated with the reactivity checks and with the positive and solvent/vehicle controls, and use these data to confirm that the reproducibility of the test method in their laboratory is maintained over time.

## PROCEDURE

16. The Standard Operating Procedures (SOP) for the IL-2 Luc assay are available and should be employed when performing the test (28). The following paragraphs provide a description of the main components and procedures of the assay.

### *Preparation of cells*

17. On receipt, 2H4 cells are propagated (2-4 passages) and stored frozen as a homogeneous stock. Cells from this stock can be propagated up to a maximum of 12 passages or a maximum of 6 weeks. The medium used for propagation is the RPMI-1640 culture medium containing 10% foetal bovine serum (FBS), antibiotic/antimycotic solution (100 U/mL of penicillin G, 100  $\mu\text{g/mL}$  of streptomycin and 0.25  $\mu\text{g/mL}$  of amphotericin B in 0.85% saline) (e.g. GIBCO Cat#15240-062), 0.15  $\mu\text{g/mL}$  Puromycin (e.g. CAS:58-58-2), 300  $\mu\text{g/mL}$  G418 (e.g. CAS:108321-42-2) and 200 $\mu\text{g/mL}$  hygromycin B (e.g. CAS:31282-04-9).

18. Prior to use for testing, the cells should be qualified by conducting a reactivity check. This check should be performed 1-2 weeks or 2-4 passages after thawing, using the positive controls, dexamethasone (100 µg/mL) (CAS:50-02-2, ≥ 98% purity) and cyclosporine A (100 ng/mL) (CAS:59865-13-3, ≥ 95% purity). Dexamethasone and cyclosporine A should produce a positive response to % suppression (≥35). Only cells that pass the reactivity check are used for the assay. The check should be performed according to the procedures described in paragraphs 26.

19. For testing, 2H4 cells are seeded at a density of 1 to 3 × 10<sup>5</sup> cells/mL, and pre-cultured in culture flasks for 72 to 96 hours. On the day of the test, cells harvested from the culture flask are washed with RPMI-1640 containing 10% FBS without any antibiotics, and then, resuspended with RPMI-1640 containing 10% FBS without any antibiotics at 4 × 10<sup>6</sup> cells/mL. Then, cells are distributed into a 96-well flat-bottom black plate (e.g. Corning Costar Cat#3603) with 50 µL (2 × 10<sup>5</sup> cells/well).

### ***Preparation of the test chemical and control substances***

20. The test chemical and control substances are prepared on the day of testing. For the IL-2 Luc assay, the test chemical is dissolved in distilled water or dimethyl sulfoxide (DMSO) (stock solution). The test chemical is first dissolved in distilled water.

- If the chemical is soluble at 25 mg/mL, add up to 1 ml of distilled water to 0.050 g of the test chemical in a volumetric flask. If the test chemical is not soluble at 50 mg/mL, 25 mg/mL is the highest soluble concentration. If the test chemical is soluble at 50 mg/mL, add up to 1 ml of distilled water to 0.100 g of the test chemical in a volumetric flask. If the test chemical is not soluble at 100 mg/mL, 50 mg/mL is the highest soluble concentration.
- If the test chemical is not soluble at 25 mg/ml in distilled water, the test chemical is dissolved in DMSO at 500 mg/mL. If the test chemical is not soluble at 500 mg/mL, the highest concentration is determined as the maximum dissolved concentration after dilution with DMSO at a dilution factor of 2 (see scheme in Appendix IV). Sonication and vortex may be used if needed. Centrifuge at 15,000 rpm (≈20,000 × g) for 5 minutes and confirm that it is soluble by the absence of precipitates. The test chemical should be used within 4 hours after being dissolved in distilled water or DMSO.

21. The first test run is aimed at determining the cytotoxic concentration and examining the immunotoxic potential of chemicals. Serial dilutions of distilled water or DMSO stock solutions of the test chemicals are made at a dilution factor of 2 (see Appendix IV) using a 96-well round-bottom clear plate. When the chemical is prepared in distilled water, dilute 20 µL of the diluted stock solution further with 480 µL of medium in a 96-well assay block (e.g. Corning Costar Cat#3960) and add 50 µL of the diluted solution to 50 µL of the cell suspension in a 96-well flat-bottom black plate. When the chemical is prepared in DMSO, dilute 10 µL of the diluted stock solution with 90 µL of the medium in a 96-well round-bottom clear plate, then, dilute 10 µL of the diluted solution with 490 µL of the medium in a 96-well assay block and then, add 50 µL of the diluted solution to 50 µL of the cell suspension in a 96-well flat-bottom black plate.

22. Thus, when the chemical is prepared as 100 mg/mL distilled water solution, the final concentrations of the test chemicals range from 0.004 to 2 mg/mL, and when the chemical is prepared as 500 mg/mL DMSO solution, the final concentrations of the test chemicals range from 0.001 to 0.5 mg/mL (Appendix IV).

23. In subsequent test runs (i.e., the second, third, and fourth run or replicate), the distilled water stock solution or the DMSO stock solution is made at the concentration 100 times or 2000 times higher than the concentration of cell viability 05 (CV05; the lowest concentration at which the Inh-GAPLA becomes <0.05) in the first run, respectively. If Inh-GAPLA does not decrease below 0.05 at the any concentration in the first run, the concentration of the stock solution in subsequent test runs is same as that of the first run.



24. Each concentration of test chemical should be tested in 4 wells. The samples are then mixed on a plate shaker and incubated for 6 hours at 37°C and 5% CO<sub>2</sub>.
25. After 1-hour incubation with the test chemical, the cells are stimulated with 25 nM PMA and 1 µM I<sub>o</sub> for 6 hours. For example, x10 PMA/ionomycin solution is made by diluting 2 mM PMA DMSO solution and 2 mM ionomycin ethanol solution using the medium, and 10 µL of the x10 solution PMA/ionomycin is added to 90 µL of the cell suspension containing the test chemical. Subsequently, the luciferase activity is measured as described in following paragraph 30.
26. The recommended positive controls are dexamethasone and cyclosporine A. For example, add 10 µL of 100 mg/mL dexamethasone DMSO solution or 10 µL of 100 µg/mL cyclosporine A DMSO solution to 90 µL of the medium in a 96-well round-bottom clear plate, dilute 10 µL of the diluted solution with 490 µL of the medium in a 96-well assay block and then, add 50 µL of the diluted solution to 50 µL of the cell suspension in a 96-well flat-bottom black plate. The final concentrations of dexamethasone and cyclosporine A are 100 µg/mL and 100 ng/mL, respectively. Each concentration of the positive control should be tested in 4 wells. The samples are then mixed on a plate shaker and incubated for 1 hour at 37°C and 5% CO<sub>2</sub>. The cells are stimulated with 25 nM PMA and 1 µM I<sub>o</sub> for 6 hours and subsequently the luciferase activity is measured as described in paragraph 30-33.
27. The solvent and negative control is RPMI-1640 containing 10% FBS containing 2% of distilled water or 1% DMSO. Other suitable positive or negative controls may be used if historical data are available to derive comparable run acceptance criteria.
28. Care should be taken to avoid evaporation of volatile test chemicals and cross-contamination between wells by test chemicals, e.g., by sealing the plate prior to the incubation with the test chemicals.
29. The test chemicals and solvent control require 2 to 4 runs to derive data evaluation and a prediction model (see paragraph 35 and 36). Each run is performed on a different day with fresh stock solution of test chemicals and independently harvested cells. Cells may come from the same passage.

### **Luciferase activity measurements**

30. Luminescence is measured using a 96-well microplate luminometer equipped with optical filters, e.g., Phelios (ATTO, Tokyo, Japan), Tristan 941 (Berthold, Bad Wildbad, Germany) or the ARVO series (PerkinElmer, Waltham, MA, USA). Examples of the optical filters are sharp-cut (long-pass or short-pass) filters or band-pass filters. The luminometer can be qualified to ensure reproducibility by light emitting diode (LED) reference light source (29).
31. Prior to testing, the transmission coefficients of the filters to discriminate each bioluminescence signal colour should be determined using recombinant green, orange and red emitting luciferases (30), per Appendix II.
32. One hundred µL of pre-warmed Tripluc® Luciferase assay reagent (Tripluc) is transferred to each well of the plate containing the cell suspension treated with or without chemical and with or without PMA/I<sub>o</sub>. The plate is shaken for 10 min at an ambient temperature of about 20°C. The plate is placed in the luminometer to measure the luciferase activity. Bioluminescence is measured for 3 sec each in the absence (F0) and presence (F1, F2) of the optical filters. Justification should be provided for the use of alternative settings, e.g. depending on the model of luminometer used.
33. Parameters for each concentration are calculated from the measured values, e.g., IL2LA, GAPLA, nIL2LA, Inh-GAPLA, the mean ±SD of IL2LA, the mean ±SD of GAPLA, the mean ±SD of nIL2LA, the mean ±SD of Inh-GAPLA, and % suppression using the excel-based spreadsheet available for the IL-2 Luc assay (see <https://www.oecd.org/env/ehs/testing/section4software.htm>). Definitions and calculations of the parameters

used in this paragraph, i.e. luciferase activity and suppression index are provided in Appendices II and V, respectively.

## DATA AND REPORTING

### **Data evaluation**

34. In each run, the test chemical is judged positive (immune-suppressive or -stimulatory) when all three following criteria are fulfilled:

1. The mean of % suppression is  $\geq 35$  (suppressive) or  $\leq -35$  (stimulatory) and statistically significant. The statistical significance is judged by its 95% confidence interval.
2. The outcome shows two or more consecutive statistically significant results (increase or decrease); alternatively one statistically significant result (increase or decrease) with the same trend for at least 3 consecutive data points (i.e. dose dependent trend); in this case the trend can cross the zero line, but the data point on the other side of the 0 line does not become statistically significant for the opposite effect.
3. The results are judged using only data obtained in the concentration range at which Inh-GAPLA is  $\geq 0.05$ .

Graphs illustrating criteria 2 are available in Appendix V.

In all other cases the test chemical is judged as not active (negative).

### **Prediction model**

35. The runs are repeated until two consistent positive (or negative) runs are obtained. A maximum of three runs is possible. The identification of an immunotoxicant is evaluated by the mean of % suppression and its 95% simultaneous confidence interval.

36. As already described in Paragraph 4, IL-2 exerts pleiotropic actions on CD4+ T cell differentiation via its modulation of cytokine receptor expression. Indeed, IL-2 promotes Th1 and Th2 differentiation, while it also drives Treg differentiation. Therefore, it suggests that the augmentation of IL-2 transcription can lead to either immune stimulation or immunosuppression depending on the surrounding tissue environment *in vivo*. Therefore, in this assay, a test chemical that is either stimulating or suppressing is considered positive.



**Acceptance criteria**

37. The following test acceptance criterion applies for this test:

if fold induction of nIFNLA of PMA/lo wells without chemicals  $\left( = \frac{\text{nIFNLA of 2H4 cells treated with PMA/lo}}{\text{nIFNLA of non-treated 2H4 cells}} \right)$  results in a value lower than 3.0, then the results obtained from the plate containing the control wells should be rejected.

**TEST REPORT**

38. The test report should include the following information:

## Test Chemical

- Mono-constituent substance:
  - Chemical identification, such as IUPAC or CAS name(s), CAS number(s), SMILES or InChI code, structural formula, and/or other identifiers.
  - Physical appearance, water solubility, molecular weight, and additional relevant physicochemical properties, to the extent available;
  - Purity, chemical identity of impurities as appropriate and practically feasible, etc.
  - Treatment prior to testing, if applicable (e.g., warming, grinding);
  - Concentration(s) tested.
  - Storage conditions and stability to the extent available;
  - Justification for choice of solvent/vehicle for each test chemical if distilled water or DMSO has not been used.
- Multi-constituent substance, UVCB and mixture:
  - Characterisation as far as possible by e.g., chemical identity (see above), purity, quantitative occurrence and relevant physicochemical properties (see above) of the constituents, to the extent available.
  - Physical appearance, water solubility, and additional relevant physicochemical properties, to the extent available.
  - Molecular weight or apparent molecular weight in case of mixtures/polymers of known compositions or other information relevant for the conduct of the study;
  - Treatment prior to testing, if applicable (e.g., warming, grinding);
  - Concentration(s) tested.
  - Storage conditions and stability to the extent available.
  - Justification for choice of solvent/vehicle for each test chemical, if distilled water or DMSO has not been used.

## Controls

- Positive control:
  - Chemical identification, such as IUPAC or CAS name(s), CAS number(s), SMILES or InChI code, structural formula, and/or other identifiers;
  - Physical appearance, water solubility, molecular weight, and additional relevant physicochemical properties, to the extent available and where applicable;
  - Purity, chemical identity of impurities as appropriate and practically feasible, etc;

- Treatment prior to testing, if applicable (e.g., warming, grinding);
  - Justification for choice of solvent vehicle for each test chemical (if distilled water or DMSO has not been used).
  - Concentration(s) tested.
  - Storage conditions and stability to the extent available.
  - Reference to historical positive control results demonstrating suitable acceptance criteria, if applicable.
- Negative control:
- Chemical identification, such as IUPAC or CAS name(s), CAS number(s), and/or other identifiers.
  - Purity, chemical identity of impurities as appropriate and practically feasible, etc.
  - Physical appearance, molecular weight, and additional relevant physicochemical properties in the case other negative controls than those mentioned in the Test Guideline are used and to the extent available;
  - Storage conditions and stability to the extent available.
  - Justification for choice of solvent for each test chemical.

#### Test method conditions

- Name and address of the sponsor, test facility and study director;
- Description of test method used.
- Cell line used, its storage conditions, and source (e.g., the facility from which it was obtained).
- Lot number and origin of FBS, supplier name, lot number of 96-well flat-bottom black plate, and lot number of Tripluc reagent;
- Passage number and cell density used for testing.
- Cell counting method used for seeding prior to testing and measures taken to ensure homogeneous cell number distribution.
- Luminometer used (e.g., model), including instrument settings, luciferase substrate used, and demonstration of appropriate luminescence measurements based on the control test described in Appendix II;
- The procedure used to demonstrate proficiency of the laboratory in performing the test method (e.g., by testing of proficiency substances) or to demonstrate reproducible performance of the test method over time.

#### Test procedure

- Number of runs performed.
- Test chemical concentrations, application procedure and exposure time (if different from those recommended).
- Description of evaluation and decision criteria used.
- Description of study acceptance criteria used.
- Description of any modifications of the test procedure.

#### Results

- Measurements of IL2LA, IFNLA and GAPLA.
- Calculations for nIL2LA, nIFNLA, Inh-GAPLA and % suppression;

- The 95% confidence interval of % suppression.
- A graph depicting dose-response curves for induction of luciferase activity and viability.
- Description of any other relevant observations, if applicable.
- Discussion of the results
- Discussion of the results obtained with the IL-2 Luc assay.
- Consideration of the assay results in the context of an IATA, if other relevant information is available.

Any modification to the Test Guideline

Conclusion

## LITERATURE

1. Corsini, E., Roggen, E.L., 2009. Immunotoxicology: opportunities for non-animal test development. *Altern. Lab. Anim.* 37(4), 387-97.
2. OECD (2022) Detailed Review Paper: *In vitro* tests addressing immunotoxicity with a focus on immunosuppression, OECD Environment, Health and Safety publications, OECD Series on Testing and Assessment No.???. OECD, Paris, France.
3. OECD (2021) OECD Series on Adverse Outcome Pathways No. 18 , [Adverse Outcome Pathway on inhibition of calcineurin activity leading to impaired T-cell dependent antibody response](#), OECD, Paris, France.
4. Liao, W., Lin, J.X., Wang, L., Peng, L., Leonard, W.J. (2011), Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. *Nat. Immunol.* 12, 551-559.
5. Saito, R., Hirakawa, S., Ohara, H., Yasuda, M., **Yamazaki, T.**, Nishii, S., Aiba, S., 2011. Nickel differentially regulates NFAT and NF-kappaB activation in T cell signaling. *Toxicol. Appl. Pharmacol.* 254(3), 245-255.
6. **JaCVAM**, Report on a Validation Study of the IL-2 Luc Assay for Evaluating the Potential Immunotoxic Effects of Chemicals on T-Cells, [https://www.jacvam.jp/list.html\(2020a\)](https://www.jacvam.jp/list.html(2020a))
7. Kimura, Y., Yasuno, R., Watanabe, M., Kobayashi, M., Iwaki, T., Fujimura, C., Ohmiya, Y., Yamakage, K., Nakajima, Y., Kobayashi, M., Mashimo, N., Takagi, Y., Omori, T., Corsini, E., Germolec, D., Inoue, T., Rogen, EL., Kojima, H., Aiba, S., 2020. An international validation study of the IL-2 Luc assay for evaluating the potential immunotoxic effects of chemicals on T cells and a proposal for reference data for immunotoxic chemicals. *Toxicol. in Vitro* 66. doi: 10.1016/j.tiv.2020.104832.
8. JaCVAM, IL-2 Luc assay peer review report, [https://www.jacvam.jp/list.html\(2020b\)](https://www.jacvam.jp/list.html(2020b))
9. Adler, S., Basketter, D., Creton, S., et al., 2011. Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. *Arch Toxicol* 85, 367-485.
10. Gennari, A., Ban, M., Braun, A., Casati, S., Corsini, E., Dastych, J., Descotes, J., Hartung, T., Hooghe-Peters, R., House, R., Pallardy, M., Pieters, R., Reid, L., Tryphonas, H., Tschirhart, E., Tuschl, H., Vandebriel, R., Gribaldo, L., 2005. The Use of *In Vitro* Systems for Evaluating Immunotoxicity: The Report and Recommendations of an ECVAM Workshop. *J. Immunotoxicol.* 2(2), 61-83.
11. Galbiati, V., Mitjans, M. & Corsini, E., 2010. Present and future of *in vitro* immunotoxicology in drug development. *J. Immunotoxicol.* 7(4), 255-267.
12. Lankveld, D.P., Van Loveren, H., Baken, K.A., Vandebriel, R.J., 2010. *In vitro* testing for direct immunotoxicity: state of the art. *Methods Mol. Biol.* 598, 401-423.
13. Kimura, Y., Fujimura, C., Ito, Y., Takahashi, T., Aiba, S., 2014. Evaluation of the Multi-ImmunoTox Assay composed of 3 human cytokine reporter cells by examining immunological effects of drugs. *Toxicol. in Vitro* 28(5), 759-768.
14. Kimura, Y., Fujimura, C., Ito, Y., Takahashi, T., Terui, H., Aiba, S., 2018. Profiling the immunotoxicity of chemicals based on *in vitro* evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. *Arch. Toxicol.* 92(6), 2043-2054.
15. Thorne, N., Inglese, J., Auld, D.S. (2010), Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. *Chem Biol* 17: 646-657, 10.1016/j.chembiol.2010.05.012
16. Ohtsuka, T., Jiziro, Y., Satoh, T., (1996), Analysis of the T-cell activation signaling pathway mediated by tyrosine kinase, protein kinase C, and Ras protein, which is mediated by

- intracellular cyclic AMP. *Biochem Biophys Acta*. 1310: 2223-232. 10.1016/0167-4889(95)00172-7
17. Shao, J., Katika, MR., Schmeits, PCJ., Mendriksen, PJM., van Lovere, H., Peijnenburg, ACM., Volger, OL., (2013), Toxicogenomics-based identification of mechanisms for direct immunotoxicity. *Toxicol Sci* 135: 328-346. 10.1093/toxsci/kft151
  18. Nakajima, Y., Kimura, T., Sugata, K., et al. (2005), Multicolor luciferase assay system: one-step monitoring of multiple gene expressions with a single substrate. *Biotechniques* 38: 891-894, 10.2144/05386ST03.
  19. Nakajima, Y., Ohmiya, Y., (2010), Bioluminescence assays: multicolor luciferase assay, secreted luciferase assay and imaging luciferase assay. *Exp. Opin. Drug Discov.* 5: 835-849, 10.1517/17460441.2010.506213.
  20. Ohmiya, Y., Sumiya, M., Viviani, V.R., Ohba, N. (2000), Comparative aspects of a luciferase molecule from Japanese luminous beetle, *Rhagophthalmus ohbai*. *Sci. Rept. Yokosuka City Mus.* 47:31-38.
  21. Viviani, V., Uchida, A., Suenaga, N., et al. (2001), Thr226 is a key residue for bioluminescence spectra determination in beetle luciferases. *Biochem Biophys Res Commun* 280: 1286-1291, 10.1006/bbrc.2001.4254
  22. Viviani, V.R., Bechara, E.J., Ohmiya, Y. (1999), Cloning, sequence analysis, and expression of active *Phrixothrix* railroad-worms luciferases: relationship between bioluminescence spectra and primary structures. *Biochemistry* 38: 8271-8279, 10.1021/bi9900830
  23. Edwards, D.R., Denhardt, D.T. (1985), A study of mitochondrial and nuclear transcription with cloned cDNA probes. Changes in the relative abundance of mitochondrial transcripts after stimulation of quiescent mouse fibroblasts. *Exp Cell Res* 157: 127-143.
  24. Mori, R., Wang, Q., Danenberg, K.D., et al. (2008), Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. *Prostate* 68: 1555-1560, 10.1002/pros.20815
  25. Winer, J., Jung, C.K., Shackel, I., et al. (1999), Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. *Anal Biochem* 270: 41-49, 10.1006/abio.1999.4085
  26. Kimura, Y., Fujimura, C., Ito, Y., Takahashi, T., Nakajim, Y., Ohmiya, Y., Aiba, S., 2015. Optimization of the IL-8 Luc assay as an *in vitro* test for skin sensitization. *Toxicol in Vitro*. 29, 1816-1830.
  27. OECD (2017), Guidance document: Good In Vitro Method Practices (GIVIMP) for the Development and Implementation of In Vitro Methods for Regulatory Use in Human Safety Assessment. OECD Environment, Health and Safety publications, OECD Series on Testing and Assessment No.286. JaCVAM, IL-2 Luc assay protocol, <https://www.jacvam.jp/list.html> (2020c)
  28. JaCVAM (2020c) : Standard Operating Procedures
  29. Yasunaga, M., et al. (2017), Continuous long-term cytotoxicity monitoring in 3D spheroids of beetle luciferase-expressing hepatocytes by nondestructive bioluminescence measurement. *BMC Biotechnol.* 17: 54, 10.1186/s12896-017-0374-1
  30. Niwa, K., Ichino, Y., Kumata, S., Nakajima, Y., Hiraishi, Y., Kato, D., Viviani, V.R., Ohmiya, Y. (2010) Quantum yields and kinetics of the firefly bioluminescence reaction of beetle luciferases. *Photochem. Photobiol.* 86:1046-9.

## APPENDIX I- DEFINITIONS

**2H4:** An IL-2 reporter cell line used in IL-2 Luc assay. The human acute T lymphoblastic leukaemia cell line Jurkat was transfected the SLG, SLO and SLR luciferase genes under the control of the IL-2, IFN- $\gamma$  and GAPDH promoters, respectively.

**Accuracy:** The closeness of agreement between test method results and accepted reference values. It is a measure of test method performance and one aspect of relevance. The term is often used interchangeably with concordance to mean the proportion of correct outcomes of a test method.

**AOP (Adverse Outcome Pathway):** Sequence of events from the chemical structure of a target chemical or group of similar chemicals through the molecular initiating event to an *in vivo* outcome of interest.

**CV05:** Cell viability 05. Minimum concentration at which chemicals show less than 0.05 of Inh-GAPLA.

**GAPLA:** Luciferase activity of stable luciferase red (SLR) ( $\lambda_{\max}$  = 630 nm), regulated by GAPDH promoter and demonstrates cell viability and viable cell number.

**Hazard:** Inherent property of an agent or situation having the potential to cause adverse effects when an organism, system or (sub) population is exposed to that agent.

**IATA (Integrated Approach to Testing and Assessment):** A structured approach used for hazard identification (potential), hazard characterisation (potency) and/or safety assessment (potential/potency and exposure) of a chemical or group of chemicals, which strategically integrates and weights all relevant data to inform regulatory decision regarding potential hazard and/or risk and/or the need for further targeted and therefore minimal testing.

**IFNLA:** Luciferase activity of stable luciferase orange (SLO) ( $\lambda_{\max}$  = 580 nm), regulated by interferon (IFN)-  $\gamma$  promoter.

**II-SLR-LA:** Abbreviation used in the validation report and in previous publications regarding the refer to Inh-GAPLA. See Inh-GAPLA for definition.

**IL-2 (Interleukin-2):** A cytokine derived from T lymphocytes that causes activation of T lymphocytes, B lymphocytes, monocyte and natural killer cells.

**IL2LA:** Luciferase activity of stable luciferase green (SLG) ( $\lambda_{\max}$  = 550 nm), regulated by IL-2 promoter.

**Inh-GAPLA:** Inhibition of GAPLA. It is obtained by dividing GAPLA of 2H4 treated with chemicals with GAPLA of non-treated 2H4 and represents cytotoxicity of chemicals.

**Minimum induction threshold (MIT):** the lowest concentration at which a chemical satisfies the positive criteria.

**Mixture:** A mixture or a solution composed of two or more substances in which they do not react.

**Mono-constituent substance:** A substance, defined by its quantitative composition, in which one main constituent is present to at least 80% (w/w).

**Multi-constituent substance:** A substance, defined by its quantitative composition, in which more than one of the main constituents is present in a concentration  $\geq 10\%$  (w/w) and  $< 80\%$  (w/w). A multi-constituent substance is the result of a manufacturing process. The difference between mixture and multi-constituent substance is that a mixture is obtained by blending of two or more substances without chemical reaction. A multi-constituent substance is the result of a chemical reaction.

**nIL2LA:** The SLG luciferase activity reflecting IL-2 promoter activity (IL2LA) normalised by the SLR luciferase activity reflecting GAPDH promoter activity (GALPA). It represents IL-2 promoter activity after considering cell viability or cell number.

**nSLG-LA:** Abbreviation used in previous publications regarding the IL-2 Luc assay to refer to nIL2LA. See nIL2LA for definition.

**nSLO-LA:** Abbreviation used in previous publications regarding the IL-2 Luc assay to refer to nIFNLA. See nIFNLA for definition.

**Positive control:** A replicate containing all components of a test system and treated with a substance known to induce a positive response. To ensure that variability in the positive control response across time can be assessed, the magnitude of the positive response should not be excessive.

**Relevance:** Description of relationship of the test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the extent to which the test correctly measures or predicts the biological effect of interest. Relevance incorporates consideration of the accuracy (concordance) of a test method.

**Reliability:** Measures of the extent that a test method can be performed reproducibly within and between laboratories over time, when performed using the same protocol. It is assessed by calculating intra- and inter-laboratory reproducibility and intra-laboratory repeatability.



**Sensitivity:** The proportion of all positive/active chemicals that are correctly classified by the test. It is a measure of accuracy for a test method that produces categorical results, and is an important consideration in assessing the relevance of a test method.

**SLG-LA:** Abbreviation used in previous publications regarding the IL-2 Luc assay to refer to IL2LA. See IL2LA for definition.

**SLO-LA:** Abbreviation used in previous publications regarding the IL-2 Luc assay to refer to IFNLA. See IFNLA for definition.

**SLR-LA:** Abbreviation used in previous publications regarding the IL-2 Luc assay to refer to GAPLA. See GAPLA for definition.

**Solvent/vehicle control:** An untreated sample containing all components of a test system except of the test chemical, but including the solvent/vehicle that is used. It is used to establish the baseline response for the samples treated with the test chemical dissolved or stably dispersed in the same solvent/vehicle. When tested with a concurrent medium control, this sample also demonstrates whether the solvent/vehicle interacts with the test system.

**Specificity:** The proportion of all negative/inactive chemicals that are correctly classified by the test. It is a measure of accuracy for a test method that produces categorical results and is an important consideration in assessing the relevance of a test method.

**Substance:** Chemical elements and their compounds in the natural state or obtained by any production process, including any additive necessary to preserve the stability of the product and any impurities deriving from the process used, but excluding any solvent which may be separated without affecting the stability of the substance or changing its composition.

**Test chemical:** The term "test chemical" is used to refer to what is being tested.

**UVCB:** substances of unknown or variable composition, complex reaction products or biological materials.

**Valid test method:** A test method considered to have sufficient relevance and reliability for a specific purpose and which is based on scientifically sound principles. A test method is never valid in an absolute sense, but only in relation to a defined purpose.

## APPENDIX II - PRINCIPLE OF MEASUREMENT OF LUCIFERASE ACTIVITY AND DETERMINATION OF THE TRANSMISSION COEFFICIENTS OF OPTICAL FILTER FOR SLG, SLO AND SLR

Multi Reporter Assay System -Tripluc- can be used with a microplate-type luminometer with a multi-colour detection system, which can equip at least two kinds of optical filters (e.g. Phelios AB-2350 (ATTO), ARVO (PerkinElmer), Tristar LB941 (Berthold)). Examples of the optical filters used in measurement are a 560 nm long-pass filter and a 600 nm long-pass filter.

(1) Measurement of three-color luciferase with two optical filters.

This is an example using Phelios AB-2350 (ATTO). This luminometer equips a 560 nm long-pass (LP) filter (560 nm LP, Filter 1) and a 600 nm long pass filter (600 nm LP, Filter 2) for optical isolation.

First, using recombinant luciferase enzyme of SLG ( $\lambda_{\max} = 550$  nm), SLO ( $\lambda_{\max} = 580$  nm) and SLR ( $\lambda_{\max} = 630$  nm), measure i) the intensity of light without filter (all optical), ii) the intensity of 560 nm LP (Filter 1) transmitted light iii) the intensity of 600 nm LP (Filter 2) transmitted light, and calculate the transmission coefficient factor listed below.

Table. Definition of the parameters in the luciferase assay

Transmission coefficient factor		Abbreviation	Definition
SLG	Filter 1 transmittance factor	$\kappa_{GR56}$	The intensity of 560 nm LP (Filter 1) transmitted SLG / the intensity of SLG without filter (all optical)
	Filter 2 transmittance factor	$\kappa_{GR60}$	The intensity of 600 nm LP (Filter 2) transmitted SLG / the intensity of SLG without filter (all optical)
SLO	Filter 1 transmittance factor	$\kappa_{OR56}$	The intensity of 560 nm LP (Filter 1) transmitted SLO / the intensity of SLO

			without filter (all optical)
	Filter 2 transmittance factor	$\kappa O_{R60}$	The intensity of 600 nm LP (Filter 2) transmitted SLO / the intensity of SLO without filter (all optical)
SLR	Filter 1 transmittance factor	$\kappa R_{R56}$	The intensity of 560 nm LP (Filter 1) transmitted SLR / the intensity of SLR without filter (all optical)
	Filter 2 transmittance factor	$\kappa R_{R60}$	The intensity of 600 nm LP (Filter 2) transmitted SLR / the intensity of SLR without filter (all optical)

When the intensity of SLG, SLO and SLR in test sample are defined as G, O and R, respectively, i) the intensity of light without filter (all optical): F0, ii) the intensity of 560 nm LP (Filter 1) transmitted light and iii) the intensity of 600 nm LP (Filter 2) transmitted light are described as below.

$$F0 = G + O + R$$

$$F1 = \kappa G_{R56} \times G + \kappa O_{R56} \times O + \kappa R_{R56} \times R$$

$$F2 = \kappa G_{R60} \times G + \kappa O_{R60} \times O + \kappa R_{R60} \times R$$

These formulas can be rephrased as follows.

$$\begin{pmatrix} F0 \\ F1 \\ F2 \end{pmatrix} = \begin{pmatrix} 1 & 1 & 1 \\ \kappa G_{R56} & \kappa O_{R56} & \kappa R_{R56} \\ \kappa G_{R60} & \kappa O_{R60} & \kappa R_{R60} \end{pmatrix} \begin{pmatrix} G \\ O \\ R \end{pmatrix}$$

Then using calculated transmission coefficient factors and measured F0, F1 and F2, you can calculate G, O and R-value as follows.

$$\begin{pmatrix} G \\ O \\ R \end{pmatrix} = \begin{pmatrix} 1 & 1 & 1 \\ \kappa G_{R56} & \kappa O_{R56} & \kappa R_{R56} \\ \kappa G_{R60} & \kappa O_{R60} & \kappa R_{R60} \end{pmatrix}^{-1} \begin{pmatrix} F0 \\ F1 \\ F2 \end{pmatrix}$$

### Materials and methods for determining transmittance factor

#### (1) Reagents

- Single purified recombinant luciferase enzymes:

- Lyophilised purified SLG enzyme

- Lyophilised purified SLO enzyme

- Lyophilised purified SLR enzyme

(which for the validation work were obtained from Tottori Bioscience Promotion Organization, Tottori, Japan with 2H4 cell line)

- Assay reagent:

- Tripluc® Luciferase assay reagent (for example from TOYOBO Cat#MRA-301)

- Medium: RPMI-1640 with 10% FBS for luciferase assay (30 ml, stored at 2 – 8°C)

#### (2) Preparation of enzyme solution

Dissolve lyophilised purified luciferase enzyme in tube by adding 200 µL of 10 ~ 100 mM Tris/HCl or Hepes/HCl (pH 7.5 ~ 8.0) supplemented with 10% (w/v) glycerol, divide the enzyme solution into 10 µL aliquots in 1.5 ml disposable tubes and store them in a freezer at -80°C. The frozen enzyme solution can be used for up to 6 months. When used, add 1 ml of medium for luciferase assay (RPMI-1640 with 10% FBS) to each tube containing the enzyme solutions (diluted enzyme solution) and keep them on

ice to prevent deactivation.

### (3) Bioluminescence measurement

Thaw Tripluc® Luciferase assay reagent (Tripluc) and keep it at room temperature either in a water bath or at ambient air temperature. Power on the luminometer 30 min before starting the measurement to allow the photomultiplier to stabilise. Transfer 100 µL of the diluted enzyme solution to a black 96 well plate (flat bottom) (the SLG reference sample to #B1, #B2, #B3, the SLO reference sample to #D1, #D2, #D3, the SLR reference sample to #F1, #F2, #F3). Then, transfer 100 µL of pre-warmed Tripluc to each well of the plate containing the diluted enzyme solution using a pipette. Shake the plate for 10 min at room temperature (about 25°C) using a plate shaker. Remove bubbles from the solutions in wells if they appear. Place the plate in the luminometer to measure the luciferase activity. Bioluminescence is measured for 3 sec each in the absence (F0) and presence (F1, F2) of the optical filter.

Transmission coefficient of the optical filter was calculated as follows:

Transmission coefficient (SLG ( $\kappa_{GR56}$ )) = (#B1 of F1+ #B2 of F1+ #B3 of F1) / (#B1 of F0+ #B2 of F0+ #B3 of F0)

Transmission coefficient (SLO ( $\kappa_{OR56}$ )) = (#D1 of F1+ #D2 of F1+ #D3 of F1) / (#D1 of F0+ #D2 of F0+ #D3 of F0)

Transmission coefficient (SLR ( $\kappa_{RR56}$ )) = (#F1 of F1+ #F2 of F1+ #F3 of F1) / (#F1 of F0+ #F2 of F0+ #F3 of F0)

Transmission coefficient (SLG ( $\kappa_{GR60}$ )) = (#B1 of F2+ #B2 of F2+ #B3 of F2) / (#B1 of F0+ #B2 of F0+ #B3 of F0)

Transmission coefficient (SLO ( $\kappa_{OR60}$ )) = (#D1 of F2+ #D2 of F2+ #D3 of F2) / (#D1 of F0+ #D2 of F0+ #D3 of F0)

Transmission coefficient (SLR ( $\kappa_{RR60}$ )) = (#F1 of F2+ #F2 of F2+ #F3 of F2) / (#F1 of F0+ #F2 of F0+ #F3 of F0)

Calculated transmittance factors are used for all the measurements executed using the same luminometer.

### *Quality control of equipment*

The procedures described in the IL-2 Luc protocol should be used (JaCVAM, 2020c).

## APPENDIX III - PROFICIENCY SUBSTANCES

Prior to routine use of the test method described in this Test Guideline, laboratories should demonstrate technical proficiency, using the 9 Proficiency Substances listed in this Appendix in compliance with the Good in vitro Method Practices (1). Moreover, test method users should maintain a historical database of data generated with the reactivity checks (see paragraph 18) and with the positive and solvent/vehicle controls (see paragraphs 26-27), and use these data to confirm the reproducibility of the test method in their laboratory is maintained over time.

1. OECD (2017), Draft Guidance document: *Good In Vitro Method Practices (GIVIMP) for the Development and Implementation of In Vitro  $\text{in vitro}$  Methods for Regulatory Use in Human Safety Assessment*. Organisation for Economic Cooperation and Development, Paris.

Table 1: Recommended substances for demonstrating technical proficiency with the IL-2\_Luc assay

No.	Chemical name	CAS No.	T cell targeting	Physical state	Reference range ( $\mu\text{g}/\text{mL}$ ) CV05 <sup>1</sup>	Reference range ( $\mu\text{g}/\text{mL}$ ) MIT <sup>2</sup>
1	Dexamethasone	50-02-2	Yes	Solid	>2000	16-63
2	Cyclosporine	59865-13-3	Yes	Solid	>1	0.002-0.006
3	Lead(II) acetate trihydrate	6080-56-4	Yes	Solid	>2000	31-63
4	Indomethacin	53-86-1	Yes	Solid	500-2000	16-63
5	Perfluorooctanoic acid	335-67-1	Yes	Solid	250-1000	8-31
6	Tributyltin chloride	1461-22-9	Yes	Liquid	0.5-1.0	0.12-0.24
7	Zinc dimethyldithiocarbamate (DMDTC)	137-30-4	No	Solid	1-4	>2000
8	Mannitol	69-65-8	No	Solid	>2000	>2000
9	Acetonitril	75-05-8	No	Liquid	>2000	>2000

Abbreviations: CAS no. = Chemical Abstracts Service Registry Number

<sup>1</sup> CV05: the minimum concentration at which chemicals show less than 0.05 of Inh-GAPLA.

<sup>2</sup> MIT: the lowest concentrations at which a chemical satisfies the positive criteria.

# APPENDIX IV – TEST CHEMICALS DISSOLUTION IN THE IL-2 LUC ASSAY.

Fig. 1 Dissolution by vehicle






Fig. 2 The scheme of the procedure when the chemical is prepared in distilled water at 100 mg/mL.




Fig. 3 The scheme of the procedure when the chemical is prepared in DMSO at 500 mg/mL.





Fig. 4 Determination of the concentration of the test chemicals in subsequent test runs (i.e., the second, third, and fourth experiment)



## APPENDIX V – CALCULATION OF THE SUPPRESSION INDEXES

### IL2LA

The j-th repetition (j= 1 to 4) of the i-th concentration (i = 0 to 10) is measured for IL2LA and GAPLA respectively. The normalized IL2LA is referred as nIL2LA, and is defined as

$$nIL2LA_{ij} = IL2LA_{ij} / GAPLA_{ij}$$

This is the basic unit of measurement in this assay.

### % suppression

The % suppression is an index for the averaged nIL2LA for the repetition on the i-th concentration compared with it on the 0 concentration, it is the primary measure of this assay. The % suppression is able to write by the following formula,

$$\% \text{ suppression}_i = \left\{ 1 - \frac{\left(\frac{1}{4}\right) \sum_i nIL2LA_{ij}}{\left(\frac{1}{4}\right) \sum_i nIL2LA_{0j}} \right\} \times 100 \quad (1)$$

The lead laboratory has proposed that  $\pm 35$  of the value suggests suppressive and stimulatory for a tested chemical. This value is based on the investigation of the historical data of the lead laboratory. Data management team followed to use the value through all the phase of present validation study.

The primary outcome measure, % suppression, is basically the ratio of 2 arithmetic means of nIL2LA as shown in equation (1). The 95% confidence interval (95% CI) of the % suppression for the i-th concentration can be estimated.

The lower limit of the 95% CI above 0 is interpreted as that the nIL2LA with the i-th concentration is statistical-significantly greater than it with the 0-concentration, whereas the upper limit of the 95% CI blow 0 is interpreted as that the nIL2LA with the i-th concentration is statistical-significantly lesser than it with the 0-concentration.

There are several ways to construct the 95% CI. We used the method kwon as the Delta method in this study. This 95% confidence interval theorem is obtained from the following formula.

$$\% \text{suppression} \pm 100 \times \left\{ z_{0.975} \times \sqrt{\frac{sd_i^2}{mean_0^2} + \frac{mean_i^2 \times sd_0^2}{mean_0^4}} \right\},$$

where  $mean_i$  is the mean of nIL2LA at the i-th concentration,  $mean_0$  is the mean of nIL2LA at 0 concentration,  $sd_i$  is the standard deviation of nIL2LA at the i-th concentration and  $sd_0$  is the standard deviation of nIL2LA at 0 concentration.  $z_{0.975}$  is 97.5 percentile of the standard normal distribution.

***Inh-GAPLA***

The Inh-GAPLA is a ratio of the averaged GAPLA for the repetition of the i-th concentration compared with it of the 0 concentration, and this is written by

$$\text{Inh-GAPLA}_i = \left\{ (1/4) \times \sum \text{GAPLA}_{ij} \right\} / \left\{ (1/4) \times \sum \text{GAPLA}_{0j} \right\}$$

Since the GAPLA is the denominator of the nIL2LA, the extremely smaller value of this is considered to cause the large variation of the nIL2LA. Therefore, the i-th %suppression value with extremely smaller value of the Inh-GAPLA might be poor precision.

***Judgment for “Suppressive”, “Stimulatory” or “No effect” in each experiment***

Criteria to judge a positive effect (either suppressive or stimulatory) are provided in the section “Data evaluation”, paragraph 34, and illustrated through Figure 1 below, extracted from Appendix 17 of the validation report.

Paragraph 34 says that an experiment is judged positive when all three following criteria are fulfilled:

1. The mean of % suppression is  $\geq 35$  (suppressive) or  $\leq -35$  (stimulatory) and statistically significant. The statistical significance is judged by its 95% confidence interval.
2. The outcome shows two or more consecutive statistically significant results (increase or decrease); alternatively one statistically significant result (increase or decrease) with the same trend for at least 3 consecutive data points (i.e. dose dependent trend); in this case the trend can cross the zero line, but the data point on the other side of the 0 line does not become statistically significant for the opposite effect.
3. The results are judged using only data obtained in the concentration range at which Inh-GAPLA is  $\geq 0.05$ .

The following four representative graphs that are judged as positive (either suppressive or stimulatory).




Fig. 1. Four patterns showing one positive data point (increase or decrease) with the same trend for at least 3 consecutive data points

The x-axis represents the chemical concentration and the y-axis represents % suppression. Each plot is the % suppression value from quadruple assays with 95% confidence intervals. The red lines indicate 35 and -35, respectively. All graphs show one positive data point (increase or decrease) with the same trend for at least 3 consecutive data points (i.e. concentration dependent trend) and the trends cross the zero line. A and C are judged as suppression and stimulation, respectively, because the 95% confidence interval of the data point indicating the opposite response (#) crosses 0. In contrast, B and D are judged negative because the 95% confidence interval of the data point indicating the opposite response (#) does not cross 0.